DK0670729T3 - Anvendelse af insulin-lignende vækstfaktorer og analoger til behandling af retinale nervesygdomme - Google Patents

Anvendelse af insulin-lignende vækstfaktorer og analoger til behandling af retinale nervesygdomme

Info

Publication number
DK0670729T3
DK0670729T3 DK92924246T DK92924246T DK0670729T3 DK 0670729 T3 DK0670729 T3 DK 0670729T3 DK 92924246 T DK92924246 T DK 92924246T DK 92924246 T DK92924246 T DK 92924246T DK 0670729 T3 DK0670729 T3 DK 0670729T3
Authority
DK
Denmark
Prior art keywords
analogues
insulin
treatment
growth factors
retinal nerve
Prior art date
Application number
DK92924246T
Other languages
Danish (da)
English (en)
Inventor
Michael E Lewis
Nicola Neff
Mohamed Iqbal
Donna Bozyczko-Coyne
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Application granted granted Critical
Publication of DK0670729T3 publication Critical patent/DK0670729T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N57/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds
    • A01N57/18—Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds having phosphorus-to-carbon bonds
    • A01N57/20—Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds having phosphorus-to-carbon bonds containing acyclic or cycloaliphatic radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/301—Acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
    • C07F9/3813—N-Phosphonomethylglycine; Salts or complexes thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/839—Nerves; brain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Pest Control & Pesticides (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Agronomy & Crop Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Environmental Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK92924246T 1991-11-08 1992-11-03 Anvendelse af insulin-lignende vækstfaktorer og analoger til behandling af retinale nervesygdomme DK0670729T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79069091A 1991-11-08 1991-11-08
US07/963,329 US6310040B1 (en) 1991-11-08 1992-10-15 Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
PCT/US1992/009443 WO1993008826A1 (fr) 1991-11-08 1992-11-03 Traitement des troubles neuronaux retiniens par application de facteurs de croissance semblables a l'insuline et des analogues de ceux-ci

Publications (1)

Publication Number Publication Date
DK0670729T3 true DK0670729T3 (da) 2001-12-10

Family

ID=27121062

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92924246T DK0670729T3 (da) 1991-11-08 1992-11-03 Anvendelse af insulin-lignende vækstfaktorer og analoger til behandling af retinale nervesygdomme

Country Status (9)

Country Link
US (1) US6310040B1 (fr)
EP (1) EP0670729B1 (fr)
JP (1) JP3445269B2 (fr)
AT (1) ATE204176T1 (fr)
CA (1) CA2122340C (fr)
DE (1) DE69232008T2 (fr)
DK (1) DK0670729T3 (fr)
ES (1) ES2160581T3 (fr)
WO (1) WO1993008826A1 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6310040B1 (en) 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
JPH09509140A (ja) * 1993-11-15 1997-09-16 セルトリックス ファーマシューティカルズ，インコーポレイテッド 神経学的障害の治療方法
US5712249A (en) * 1994-09-08 1998-01-27 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
WO1996007744A1 (fr) * 1994-09-08 1996-03-14 Chiron Corporation Procede de production amelioree des facteurs de croissance proches de l'insuline
JP3191038B2 (ja) 1996-06-26 2001-07-23 輝夫 西田 眼科用医薬組成物
WO2000053760A2 (fr) * 1999-03-12 2000-09-14 Genentech, Inc. Technique permettant de prevenir la mort des neurones retiniens et traitement des maladies oculaires
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
EP1005869A4 (fr) * 1997-03-24 2004-06-23 Fujisawa Pharmaceutical Co Secretagogues de bile
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6331523B1 (en) 1998-03-12 2001-12-18 Genentech, Inc. Method of enhancing the survival of retinal neurons and treating ocular diseases using FGF-5
US6875741B2 (en) 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
US7173005B2 (en) 1998-09-02 2007-02-06 Antyra Inc. Insulin and IGF-1 receptor agonists and antagonists
DK1141014T3 (da) 1999-01-06 2005-04-11 Genentech Inc Insulinlignende vækstfaktor (IGF) i mutantvariant
AU6391000A (en) * 1999-07-28 2001-02-19 Genentech Inc. Method of preventing the injury or death of retinal cells and treating ocular diseases
GB9928323D0 (en) * 1999-11-30 2000-01-26 Cyclacel Ltd Peptides
US20050245451A1 (en) * 2000-04-05 2005-11-03 Pincus Matthew R Peptides selectively lethal to malignant and transformed mammalian cells
ATE389416T1 (de) 2000-05-16 2008-04-15 Genentech Inc Behandlung von knorpelerkrankungen
AU7511101A (en) * 2000-05-31 2001-12-11 Us Gov Health & Human Serv Use of activity-dependent neurotrophic factor-derived polypeptides for enhancinglearning and memory: pre- and post-natal administration
HUP0500733A3 (en) 2001-02-09 2010-01-28 Genentech Inc Crystallization of igf-1
AU2002303856A1 (en) 2001-05-24 2002-12-03 Neuronz Limited Gpe analogs and peptidomimetics
US7605177B2 (en) 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
TWI305778B (en) * 2001-12-03 2009-02-01 Nishida Teruo Peptides of an expressing unit for igf-i minimal activity and their pharmaceutical use
JP4253743B2 (ja) * 2001-12-03 2009-04-15 輝夫 西田 新規ペプチドおよびその医薬用途
EP1841443A4 (fr) * 2005-01-11 2012-05-02 Heart Failure Technologies Inc Methode et systeme pour le traitement de l'insuffisance cardiaque
JP2008538501A (ja) * 2005-04-20 2008-10-30 オークランド ユニサービシーズ リミティド ベシキュリン
US8309057B2 (en) * 2005-06-10 2012-11-13 The Invention Science Fund I, Llc Methods for elevating neurotrophic agents
EP2270039B1 (fr) * 2006-03-06 2013-05-29 Caregen Co., Ltd. Peptides dotés d'activités de l'insuline de type facteur de croissance 1 et leurs utilisations
EP2224961A1 (fr) * 2007-11-26 2010-09-08 The Research Foundation of the State University of New York Traitements du cancer par petites molécules provoquant une nécrose dans des cellules cancéreuses, mais n'affectant pas les cellules normales
DK2279210T3 (en) 2008-05-07 2017-07-24 Biomarin Pharm Inc Lysosomal targeting peptides and uses thereof
US9132202B2 (en) 2009-07-17 2015-09-15 Aaron T. Tabor Compositions and methods for genetic modification of cells having cosmetic function to enhance cosmetic appearance
CA2768621C (fr) 2009-07-22 2016-04-05 Ipsen Pharma S.A.S. Analogues au facteur-1 de croissance insulinomimetique (igf-1) presentant une substitution d'acide amine en position 59
WO2011011073A1 (fr) * 2009-07-22 2011-01-27 Ipsen Pharma S.A.S. Igf-1 pégylé spécifique de site ou lipidé spécifique de site et analogues de l’igf-1
TWI490371B (zh) 2009-07-28 2015-07-01 Industrie De Nora Spa 電解應用上的電極及其製法以及在電極表面上陽極釋氧之電解法和電冶法
EP2509596B1 (fr) 2009-12-08 2019-08-28 Case Western Reserve University Gamma acides aminés pour le traitement de troubles oculaires
KR101669140B1 (ko) * 2015-04-28 2016-10-26 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
CN111763680A (zh) * 2019-05-22 2020-10-13 杭州杰迪生物科技有限公司 一种人胰岛素样生长因子-i或其类似物的制备方法、编码基因、表达载体及宿主细胞

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077276A (en) * 1985-08-22 1991-12-31 Gropep Pty Ltd Growth factor
US4783524A (en) 1985-09-17 1988-11-08 Monsanto Company Growth factors
SE8505920D0 (sv) 1985-12-13 1985-12-13 Kabigen Ab New protein and its use
DE3851776T2 (de) 1987-04-28 1995-05-04 Boehringer Mannheim Gmbh Verwendung von IGF-II zur Behandlung von Knochenkrankheiten.
SE8703625D0 (sv) * 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
EP0346429B1 (fr) 1987-12-24 1994-12-28 Gropep Pty. Ltd. Analogues peptidiques du facteur 1 (igf-1) ou du facteur 2 (igf-2) de croissance similaire a l'insuline
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
US5652214A (en) * 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
CA2114251C (fr) * 1991-08-01 2007-11-06 Peter Gluckman Igf-1 permettant d'ameliorer l'etat du systeme nerveux
US6310040B1 (en) 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs

Also Published As

Publication number Publication date
ES2160581T3 (es) 2001-11-16
DE69232008T2 (de) 2001-11-29
EP0670729A1 (fr) 1995-09-13
CA2122340A1 (fr) 1993-05-13
WO1993008826A1 (fr) 1993-05-13
ATE204176T1 (de) 2001-09-15
EP0670729B1 (fr) 2001-08-16
EP0670729A4 (fr) 1995-05-10
DE69232008D1 (de) 2001-09-20
US6310040B1 (en) 2001-10-30
JP3445269B2 (ja) 2003-09-08
CA2122340C (fr) 2007-06-12
JPH07500839A (ja) 1995-01-26

Similar Documents

Publication Publication Date Title
DK0670729T3 (da) Anvendelse af insulin-lignende vækstfaktorer og analoger til behandling af retinale nervesygdomme
CA2058443A1 (fr) Traitement de certains troubles par application de facteurs de croissance insulinoides et de leurs analogues
ATE112684T1 (de) Verwendung von igf-ii zur behandlung von knochenkrankheiten.
ES2043890T3 (es) Nuevo uso medico.
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
DE3779149D1 (de) Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit.
ATE433324T1 (de) Verwendung von glp-1 oder analoge zur behandlung von schlaganfall
DK1316308T3 (da) Transdermalt terapeutisk plaster med capsaicin og capsaicin-analoger
GR3026602T3 (en) Morphogen-induced liver regeneration.
EP0214017A3 (en) Use of n,n,-dimethylbiguanid p-chorophenoxyacetate in the treatment of neuropathies and nerval degeneration
SG48733A1 (en) Use of il-10 to prevent or treat insulin-dependent diabetes mellitus
EP0515434A4 (en) Method for treating intestinal diseases
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
NO933742L (no) Humant, benavledet, insulinlignende vekstfaktorbindingsprotein
AR003979A1 (es) Administracion transdermica de vorozol.
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
DE69124382D1 (de) Authentischen igf-1 und hypokalorische menge von nährstoffen enthaltendes produkt und dessen verwendung zur behandlung kataboler zustände
SE9101341D0 (sv) New medicinal use
葛通远 et al. AN APPROACH TO THE MECHANISMS OF LASER ACUPUNCTURE IN TREATMENT OF EXOPHTHALMIC HYPERTHYROIDISM
UA10224A (uk) Спосіб лікування хронічного бронхіту на фоні цукрового діабету